Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis
Version of Record online: 20 MAR 2008
European Journal of Clinical Investigation
Volume 22, Issue 12, pages 783–792, December 1992
How to Cite
BYGREN, P., RASMUSSEN, N., ISAKSSON, B. and WIESLANDER, J. (1992), Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis. European Journal of Clinical Investigation, 22: 783–792. doi: 10.1111/j.1365-2362.1992.tb01447.x
- Issue online: 20 MAR 2008
- Version of Record online: 20 MAR 2008
- Received 2 March 1992 and in revised form 31 July 1992; accepted 12 August 1992
- anti-neutrophil cytoplasm antibodies
Abstract. The diagnostic potential of assays detecting anti-neutrophil cytoplasm antibodies (ANCA), anti-GBM antibodies and anti-dsDNA antibodies was evaluated by examining sera from time of admission in a consecutive series of 455 patients with biopsy verified primary or secondary glomerulonephritis (GN). ANCA were classified into c- and p-ANCA by indirect immunofluorescence (IIF) and ELISAs using alfa-granule extract, proteinase-3, myeloperoxidase (MPO), elastase and lactoferrin. C-ANCA was virtually confined to 64 patients with systemic small vessel vasculitis, 66–74% being c-ANCA positive. P-ANCA against MPO, seen in 47 patients, segregated through many diagnostic categories of primary and secondary severe GN. ANCA against lactoferrin and elastase were rare. Anti-dsDNA positive patients constituted 57% of the 44 ANA-positive patients with systemic lupus erythematosus.
It is concluded that the IIF and ELISAs for anti-proteinase-3, anti-MPO, anti-dsDNA and anti-GBM have an acceptable performance and are useful in the primary diagnostic work-up of patients suspected for secondary GN as the majority of such patients will be classified by these assays.